Alector Reports Q2 2025 Financial Results, Collaboration Revenue Declines to $7.9 Million

Alector, Inc. reported its financial results for the second quarter of 2025, revealing a collaboration revenue of $7.9 million, a significant decrease from $15.1 million in the same period last year. For the first half of 2025, collaboration revenue totaled $11.5 million, down from $31.0 million in the first half of 2024. The decline in revenue is attributed to the completion of performance obligations related to the AL002 program and the Phase 2 trial of latozinemab, which concluded in late 2024. The company incurred a net loss of $30.5 million for the quarter, an improvement compared to a net loss of $38.7 million in the prior year, while the six-month net loss was $71.0 million, down from $74.8 million.

Alector's total operating expenses for the second quarter were $42.0 million, a decrease from $60.7 million in the same quarter of 2024. This reduction was primarily driven by lower research and development expenses, which fell to $27.6 million from $46.3 million year-over-year, reflecting cost-cutting measures including a workforce reduction of approximately 13% initiated in March 2025. The company’s cash, cash equivalents, and marketable securities stood at $307.3 million as of June 30, 2025, providing a financial runway into the second half of 2027.

In terms of strategic developments, Alector continues to advance its clinical pipeline, focusing on its lead product candidates, latozinemab and AL101, which are in Phase 3 and Phase 2 trials, respectively. The company has a collaboration agreement with GlaxoSmithKline (GSK) for the development and commercialization of these candidates, which includes potential milestone payments of up to $1.5 billion. Alector is also leveraging its proprietary Alector Brain Carrier (ABC) technology to enhance drug delivery across the blood-brain barrier, aiming to improve treatment outcomes for neurodegenerative diseases.

Operationally, Alector has made significant strides in its clinical trials, completing enrollment for the pivotal INFRONT-3 trial for latozinemab in October 2023, with topline data expected by mid-fourth quarter of 2025. The company reported a total employee headcount of 163 as of June 30, 2025, reflecting its recent restructuring efforts. Alector's management remains focused on advancing its research and development programs while navigating the complexities of the biotechnology landscape, including regulatory challenges and competition from other firms in the neurodegenerative disease space.

Looking ahead, Alector anticipates continued investment in its clinical programs and research initiatives, with expectations of increased operating expenses as it progresses through various stages of drug development. The company remains committed to its mission of addressing unmet medical needs in neurodegenerative diseases, although it acknowledges the inherent risks and uncertainties associated with drug development and regulatory approval processes.